15th week of 2009 patent applcation highlights part 28 |
Patent application number | Title | Published |
20090092616 | ZNF206: A Novel Regulator of Embryonic Stem Cell Self-renewal and Pluripotency - We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely downregulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate genes associated with the pluripotent state, and may lead to the further emergence of genes associated with even more differentiated lineages and phenotypes. | 2009-04-09 |
20090092617 | Erbb Receptor-Derived Peptide Fragments - The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed. | 2009-04-09 |
20090092618 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic cardiovascular diseases including stroke, using said peptide in an assay, pharmaceutical compositions comprising the peptide. The invention further encompasses a particular peptide sequence aggravating disease, which sequence then can be used for diagnostic assays. | 2009-04-09 |
20090092619 | METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition. | 2009-04-09 |
20090092620 | FLU VIRUS HEMAGGLUTININ SPECIFIC MONOCLONAL ANTIBODIES - The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group. | 2009-04-09 |
20090092621 | ANTIBODIES FOR PREVENTING AND TREATING ATTACHING AND EFFACING ESCHERICHIA COLI (AEEC) ASSOCIATED DISEASES - The present invention relates to antibodies immunologically specific for an attaching and effacing | 2009-04-09 |
20090092622 | MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUSES - A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions. | 2009-04-09 |
20090092623 | Promoter - The present invention provides a novel polynucleotide vectors and their use in the production of biological material in host cells, and also in medical therapy or polynucleotide vaccination. The novel vectors of the present invention comprise a promoter normally associated with the US3 gene of Human Cytomegalovirus (HCMV). | 2009-04-09 |
20090092624 | Antiinfective Flavononol Compounds and Methods of Use Thereof - The present invention relates in part to antiinfective flavononol compounds represented by formula I: | 2009-04-09 |
20090092625 | PARATHYROID HORMONE RECEPTOR ACTIVATION AND HEMATOPOIETIC PROGENITOR CELL EXPANSION - The invention relates to methods for manipulating hematopoietic progenitor cells and related products In one aspect the invention relates to the use of agents that activate a PTH/PTHrP receptor to enhance the growth and maintenance of hematopoietic progenitor cells in vivo and in vitro, to enhance mobilization of hematopoietic stem cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function. | 2009-04-09 |
20090092626 | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 - A self-adjuvanting immunogenic composition comprising multiple immunogens, each immunogen comprising a lipopeptide cap, a universal T helper sequence and an immunodominant HIV-1 Tat B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The HIV-1 Tat B cell epitope of each immunogen has an amino acid sequence of V-D-P-Xaa7-L-Xaa9-P-W-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-amide SEQ ID NO: 1, in which the amino acid positions at Xaa7, Xaa9 and Xaa12 are selected from specific amino acid residues choices and in which the amino acid positions at Xaa13-Xaa16 may be absent or specific amino acid residue choices. The lipopeptide is a dipalmitoyl-S-glyceryl-cysteine or a tripalmitoyl-S-glyceryl cysteine or N-acetyl (dipalmitoyl-S-glyceryl cysteine), each with an optional neutral amino acid linker. Optional polar sequences of at least four charged polar amino acids enhance solubility of the immunogen and are located at the carboxy terminal end of the lipopeptide cap, optionally flanked by neutral linker amino acids, or elsewhere in the immunogen. In the composition, each immunogen differs from another immunogen by an amino acid variation at amino acid position Xaa7, Xaa9 or Xaa12 of the immunodominant HIV-1 Tat epitope. Such compositions can induce anti-HIV-1 Tat antibodies with geometric mean titers of greater than 1,000,000 on multiple HIV-1 Tat variants, when employed to immunize a subject, without any extrinsic adjuvant. | 2009-04-09 |
20090092627 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2009-04-09 |
20090092628 | Conserved-element vaccines and methods for designing conserved-element vaccines - Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (“CEVac”) is a recombinant and/or synthetic vaccine that incorporates only highly conserved epitopes from an observed set of pathogen variants. The conserved epitopes are identified computationally by aligning biopolymer sequences, such as concatenated polypeptide sequences that together represent a pathogen proteome, corresponding to an observed set of pathogen variants, and computationally selecting conserved subsequences according to a number of subsequence-selection criteria. These subsequence-selection criteria may include a minimum conserved-subsequence length, a threshold frequency of occurrence of a particular monomer at each conserved, single-monomer position within a conserved subsequence, a threshold combined occurrence for a set of allowable variant monomers at a particular conserved, variable position within a conserved subsequence, and a maximum number of variable positions within a subsequence. A set of conserved subsequences identified according to the subsequence-selection criteria are then filtered to remove subsequences identical to, or too similar to, naturally-occurring host subsequences, and are then assembled into expression vectors for incorporation into microbial hosts for biosynthesis of a recombinant CEVac or assembled into one or more synthetic constructs for a synthetic CEVac. | 2009-04-09 |
20090092629 | VACCINE FOR NONTYPEABLE HAEMOPHILUS INFLUENZAE INFECTION - This invention provides a method for identifying strains of nontypeable | 2009-04-09 |
20090092630 | Chimeric recombinant antigens of toxoplasma gondii - A method for treatment or prevention of | 2009-04-09 |
20090092631 | GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 2009-04-09 |
20090092632 | Methods for preparing complex multivalent immunogenic conjugates - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 2009-04-09 |
20090092633 | Polyamino acid for use as adjuvant - Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle. | 2009-04-09 |
20090092634 | Chicken Virus Vaccine and Diagnostic - A novel astrovirus designated chicken astrovirus type 3 has been isolated and characterised. Nucleotide sequences and polypeptide sequences of this astrovirus are provided with uses of the same and the isolated astrovirus in assay kits and vaccines. | 2009-04-09 |
20090092635 | HETEROLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN - The present invention is directed to a method for generating an antigen-specific immune response in a subject in general and in particular to administering a priming dose of an immunogenic composition of a recombinant mumps virus (rMuV) that encodes an antigen followed by administering a boosting dose of recombinant vesicular stomatitis virus (rVSV) encoding an antigen. | 2009-04-09 |
20090092636 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 2009-04-09 |
20090092637 | Medicaments and methods to treat autoimmune disease and cancer - The present invention relates to methods and formulations for GAD-vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a prime and boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. | 2009-04-09 |
20090092638 | POLYNUCLEOTIDES ALLOWING THE EXPRESSION AND SECRETION OF RECOMBINANT PSEUDO-VIRUS CONTAINING FOREIGN EPITOPES, THEIR PRODUCTION, AND USE - This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the invention, by expression of epitopes derived from common pathogens, by-passes existing tolerance of virus specific T cell responses. The vector will only replicate in virus infected cells. | 2009-04-09 |
20090092639 | IMMUNOGENIC COMPOSITION - Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed. | 2009-04-09 |
20090092640 | Increased T-cell tumor infiltration and eradication of metastases by mutant LIGHT - Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed. | 2009-04-09 |
20090092641 | USES OF NATURAL IMMUNOBIOTIC EXTRACT - The present invention provides a method of improving disease management in an animal by administering an effective amount of β-glucan composition to the animal. The β-glucan composition comprises at least about 70% β-(1,3/1,6)-D-glucan by dry weight and a biological activity of at least 20 μg Bb released per mg of β-(1,3/1,6)-D-glucan. The method may also result in beneficial secondary effects including an increase in growth efficiency of the animal; an increase in the survival rate of the animal; an increase in the colostrum quality of the animal; and any combination thereof. The β-glucan composition may also be administered in combination with or prior to a vaccine, leading to an increase in antibody formation; the negative growth responses associated with administration of a vaccine may also be reduced. In the present method, the β-glucan composition may be administered in combination with an animal feed. | 2009-04-09 |
20090092642 | Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure - A composition of matter that is suitable for use on skin or hair. The composition comprises one or more compounds of formula | 2009-04-09 |
20090092643 | Foam Strip for the Delivery of Oral Care Compositions - The present invention relates to a polyurethane foam strip ( | 2009-04-09 |
20090092644 | LOCKED-IN TYPE POWDER - The present invention relates to a locked-in type powder comprising polyphenols, the locked-in type powder which is excellent in long-term stability, substantially does not show decrease in color tone and discoloration even after long-term storage, also does not result in change in odor quality and decrease in deodorizing and antioxidizing effects, and is capable of retaining good effects over a long period of time, and a solid preparation comprising the same. | 2009-04-09 |
20090092645 | Radiation Method for Fabrication of Nano-sized Compound Antibacterial Fabric Textile - The invention discloses an innovative process to produce highly antibacterial nano-composite fabric textile containing silver metal compound. The process mainly uses high-energy D-ray radiation to modify silver type of bactericides and graft or crosslink them onto Nylon or PET fiber surface to produce excellent antibacterial textile products. The mechanism uses silver nano-compound as performance additive and through Co-60 irradiation technique reduces and firmly fastens silver particles onto Nylon or PET (Polyethylene Terephthalate) fiber material. Because the inorganic silver type bactericides actively interact with enzymes in bacteria or destroy cell walls to achieve good bactericidal effect, the radiation process does not need initiators or other additives. So the process is simple and effective. The test results prove excellent bactericidal power and potential value in household or medical textile products. | 2009-04-09 |
20090092646 | Effigy and Compound to Affect Bird Behavior - An exemplary device is an effigy of a bird predator treated with a compound that irritates birds via the avian trigeminal pathway. Another exemplary device is an effigy of a bird predator that includes a supply of a compound that irritates birds via the avian trigeminal pathway. An exemplary method of abating birds from a structure includes treating an effigy of a bird predator with a compound that irritates bird via the avian trigeminal pathway and positioning the treated effigy in the structure. Other exemplary devices, system and methods are also disclosed. | 2009-04-09 |
20090092647 | POLYURETHANE FOAMS FOR WOUND MANAGEMENT - The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and inorganic, cationic coagulants is frothed and dried. | 2009-04-09 |
20090092648 | ANTIMICROBIAL POLYMER COMPOSITIONS AND THE USE THEREOF - An antimicrobial composition. The antimicrobial composition includes a complex of an anionic polyester with a monomeric amidoamine a complex of an anionic polyester with a monomeric amidoamine or an organic cation, wherein the monomeric amidoamine comprises: | 2009-04-09 |
20090092649 | Method and apparatus for imparting a biocidal agent - A method and an apparatus is disclosed for using a biocidal agent associated with a sheet of material on a food item subsequent packaging of the item to maintain product properties in packaged beverages and foods. The method includes providing a sheet for imparting a biocidal activity to a food product. The sheet has a biological agent associated therewith in an amount sufficient to render it resistant to attack from organisms and in an amount that the sheet imparts biocidal activity in an area surrounding the sheet. The sheet further has at least one line of weakness to define two or more strips on the sheet, each strip having the biological agent associated therewith and each strip being selectively separable from the sheet. | 2009-04-09 |
20090092650 | Sustained Delivery Formulations of Octreotide Compounds - The present invention relates to an octreotide sustained release delivery system for treatment of diseases relating to somatotropin and/or somatostatin. The sustained release delivery system of the invention includes a flowable composition containing an octreotide compound, and an implant containing the octreotide compound. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and an octreotide compound. | 2009-04-09 |
20090092651 | ABSORBABLE ADHESIVES AND THEIR FORMULATION FOR USE IN MEDICAL APPLICATIONS - Described are medical products including an adhesive containing a polypeptide component such as gelatin and a tackiness-providing polyhydroxy compound, such as at least one compound selected from the group consisting of glycerin and fructose. Such medical products can find use as a bolster material for use in conjunction with a surgical fastening device such as a stapler. Other medical applications utilizing a medical product of the invention include tissue repair and pharmaceutical delivery to a desired location. Related methods of manufacture and use are also described. | 2009-04-09 |
20090092652 | Method for the inhibition of angiogenesis or cancer using protective antigen related molecules - The present invention is based on the discovery that protective antigen related molecules (PARMs) without anthrax lethal factor have antiangiogenic or anticancer properties. The invention is directed to a method of inhibiting an angiogenic disease/disorder or cancer. Additionally, the invention can be applied to those at risk for developing cancer or an angiogenic disease/disorder comprising administering to a mammal an angiogenesis-inhibiting or cancer inhibiting amount of an PARM (including analogs, or derivative thereof having angiogenesis-inhibiting or anticancer activity, consisting of PA, PA fragment, analog, or derivative that is administered in a composition substantially free of anthrax lethal factor or other toxins). | 2009-04-09 |
20090092653 | REPAIR AND REGENERATION OF RENAL TISSUE USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and regeneration of the diseased or damaged kidney tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided. | 2009-04-09 |
20090092654 | Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System - An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent. | 2009-04-09 |
20090092655 | NOVEL PREPOLYMERIZABLE SURFACE ACTIVE MONOMERS WITH BOTH FLUORINE-CONTAINING GROUPS AND HYDROPHILIC GROUPS - Provided are surface modified contact lenses formed from one or more fumaric- or itaconic-containing prepolymers having reactive functionality that is complimentary to surface modifying polymers. | 2009-04-09 |
20090092656 | METHOD OF TREATING ATROPHIC VAGINITIS - The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen. | 2009-04-09 |
20090092657 | Amino acid combinant omega oil aphrodisiac - A method of enhancing the libido in an adult human comprising the administering of a composition, comprising an effective amount of the amino acids tryptophan and phenylalanine and an effective amount of omega oils. | 2009-04-09 |
20090092658 | NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS - The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease including nocturnal acid breakthrough, or the symptoms associated therewith | 2009-04-09 |
20090092659 | Devices for Improved Wound Management - The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule. The nucleic acids used in the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about 1, more preferably less than pH 4.5 to about 1, and even more preferably less than pH 2 to about 1. | 2009-04-09 |
20090092660 | Methods and compositions for needleless delivery of particles - Methods and compositions for needleless delivery of particles to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a particle to be delivered to a subject, and, optionally, a cleavable linker. In other aspects, the invention provides compositions comprising delivery constructs of the invention, kits comprising delivery constructs of the invention, and methods of using delivery constructs of the invention. | 2009-04-09 |
20090092661 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS - Liposome formulations for administration of a boronic acid compound are described. The liposomes are comprised of a phospholipid having two acyl chains with between 20-22 carbon atoms in each chain and a boronic acid compound entrapped in the liposomes. In a preferred embodiment, the boronic acid compound is in the form of a complex with meglumine. | 2009-04-09 |
20090092662 | LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS - A liposome composition comprised of liposomes having a peptide boronic acid proteasome inhibitor compound entrapped in the liposomes is described. More specifically, liposomes having a compound of Formula I or II entrapped in the interior aqueous compartment are loaded with a peptide boronic acid compound, to form a boronate ester compound inside the liposomal aqueous compartment. In one embodiment, the liposomes have an outer coating of hydrophilic polymer chains and are used to treat a solid tumor in a subject. | 2009-04-09 |
20090092663 | Tumor-targeted drug delivery systems and uses thereof - The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments. | 2009-04-09 |
20090092664 | POLYMER-METAL CHELATOR CONJUGATES AND USES THEREOF - The present invention provides prodrugs comprising a polymer conjugated to a metal chelator via a disulfide bond. For example, D-penicillamine may be conjugated to a polymer (e.g., gelatin, chitosan, polyglutamic acid) via a linker, such as SPDP. Thus, the cellular delivery and pharmacokinetics of D-penicillamine can be substantially improved. Methods for the treatment of cancer using compositions of the present invention are also disclosed. | 2009-04-09 |
20090092665 | OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS - The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles. | 2009-04-09 |
20090092666 | Vaccines with enhanced immune response and methods for their preparation - The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins. | 2009-04-09 |
20090092667 | Method for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis with (-)-Nilvadipine Enantiomer - The present invention provides methods for reducing Aβ deposition, Aβ neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (−)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of Aβ deposition, Aβ neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (−)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter. | 2009-04-09 |
20090092668 | ACETAMINOPHEN FORMULATION FOR JOINT PAIN RELIEF - The invention relates generally to a formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for joint pain relief. The formulation may comprise supplements such as glucosamine, hyaluronic acid and methylsulfonylmethane (MSM) and acetaminophen for acute joint pain. The invention also encompasses methods for joint pain relief with the formulation described herein. | 2009-04-09 |
20090092669 | STABLE IMATINIB COMPOSITIONS - Formulations containing imatinib, preferably imatinib mesylate, with high polymorphic stability and the processes for the preparation thereof are disclosed. | 2009-04-09 |
20090092670 | LONG ACTING DUAL RELEASE PRODUCT CONTAINING CARBINOXAMINE AND PSEUDOEPHEDRINE - Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants. | 2009-04-09 |
20090092671 | Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction - Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ | 2009-04-09 |
20090092672 | ORALLY DISINTEGRATING TABLET COMPOSITIONS OF LAMOTRIGINE - The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients. | 2009-04-09 |
20090092673 | Biocide - A two part biocide composition containing metal ions and bromine donor for killing microorganisms in a body of water and a method of killing microorganisms in a body of water by placing both metal ions and a bromine in the body of water to allow use of lower concentrations of bromine than if bromine were used alone as a biocide. | 2009-04-09 |
20090092674 | FLOWABLE WOUND MATRIX AND ITS PREPARATION AND USE - This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth. | 2009-04-09 |
20090092675 | COMPOSITIONS CONTAINING MULTIPLE POLYMERS AND PARTICLES MADE USING THE COMPOSITIONS - The compositions described herein include a first polymer that is either a polyvinyl alcohol or a polyvinyl formal, and a second polymer that is one of a polyvinyl alcohol, a polyvinyl formal, polyvinylpyrrolidone, a polysaccharide, or a polymethacrylate. The first polymer and the second polymer in the composition are different. These compositions are useful in the formation of particles, such as embolic particles, or other medical devices. The compositions are also useful in the delivery of therapeutic agents. Different ratios of the first polymer to the second polymer can provide different rates of release of the therapeutic agent from the composition. | 2009-04-09 |
20090092676 | CROSS-LINKED POLYMER PARTICLES - Cross-linked polymer particles, as well as related compositions and methods, are disclosed. | 2009-04-09 |
20090092677 | MULTI-COMPONENT PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric component). | 2009-04-09 |
20090092678 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 2009-04-09 |
20090092679 | PARTICLE/CELL SEPARATION DEVICE AND COMPOSITIONS - A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted. | 2009-04-09 |
20090092680 | PREPARATION FOR TREATMENT OF MINERAL DEFICIENCY - The invention relates to a preparation having an improved taste, as well as to the use of said preparation for treatment of mineral deficiency. In accordance with the invention, it has been found possible to effectively mask the bad taste of even such notorious minerals as iron. As a result, patient compliance may be increased significantly by prescription of a preparation according to the invention, thereby increasing effective uptake of the deficient mineral. | 2009-04-09 |
20090092681 | ARTIFICIAL CEREBROSPINAL FLUID - The present invention provides an artificial cerebrospinal fluid containing 120 to 160 mEq/L of sodium ion, 1 to 6 mEq/L of potassium ion, 75 to 155 mEq/L of chloride ion, and 5 to 45 mEq/L of bicarbonate ion, and provides an artificial cerebrospinal fluid further containing at least one component selected from the group consisting of 10 g/L or less of a reducing sugar, 5 mmol/L or less of phosphoric acid, 5 mEq/L or less of calcium ion, and 5 mEq/L or less of magnesium ion. The artificial cerebrospinal fluid of the present invention can prevent or reduce the incidence of cerebral edema and can further suppress brain cell disorders when used as an irrigation fluid or perfusion fluid in the field of neurosurgery, such as intracranial surgery, or when used as a replenishing fluid for lost cerebrospinal fluid. | 2009-04-09 |
20090092682 | FUNGICIDAL COMPOSITION FOR THROUGH PERIDERM BARK APPLICATION TO WOODY PLANTS - A fungicidal composition for topical application to woody plant periderm, the composition comprising (a) a systemic fungicide, (b) an organosiloxane surfactant, and (c) water. | 2009-04-09 |
20090092683 | Micronized Wood Preservative Formulations - The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, there is minimal leaching of the metal and biocide from the wood. | 2009-04-09 |
20090092684 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 2009-04-09 |
20090092685 | WOUND AND ULCER TREATMENT WITH SUPER-OXIDIZED WATER - Super-oxidized water based on hypochlorous acid, such as is obtained by the electrochemical treatment of a saline solution, may be used in the treatment of leg ulcers or other open wounds. Preferably, the pH of the super-oxidized water is in a range of 4 to 7, and the water has a redox potential of >950 mV. Medicaments based on the super-oxidized water may be in liquid or gel form. The super-oxidized water is able to control the microbial population within the wound and at the same time permit cell proliferation. | 2009-04-09 |
20090092686 | PROCESS FOR THE RECOVERY OF A PHYTOLIPID COMPOSITION - Disclosed is a process for the recovery of a phytolipid composition from a vegetable oil by-product. The phytolipid composition produced comprises squalene, phytosterols, mixed tocopherols and tocotrieneols, and vegetable wax and is useful as an emollient. The phytochemical composition may be applied directly to the skin to provide emolliency. Alternatively, the phytolipid composition may be formulated in various aqueous or anhydrous cosmetic compositions such as creams, lotions, gels, ointments, lip balms, sticks, or pencils for treatment of the skin and lips. The phytolipid composition also may be incorporated into foods, beverages, and nutraceuticals to provide health benefits. | 2009-04-09 |
20090092687 | Prhormone composition and method of use thereof - The invention provides methods and compositions for maintaining a state of sexual wellness in a healthy human by providing a dietary supplement comprising one or more sexual steroid prohormones. | 2009-04-09 |
20090092688 | Ointment for topical treatment of hot flashes and method of use - A composition and method of use therefor that provides for the objective topical treatment of hot flashes that is clinically shown to objectively reduce skin temperature, with the effective ingredients including menthol and peppermint oil which can be substituted with spearmint oil. The method involves application of the composition, which can be in the form of a liquid, crème, topical gel, mist or moist towelette and which is applied most optimally to the back of the neck, the front of the neck, behind the ears and on the wrists of the sufferer. | 2009-04-09 |
20090092690 | Process of making theaflavins enriched tea extract - This invention provides various products and processes such as a process of making a theaflavins enriched extract of tea having a low content of high molecular weight thearubigins which comprises extracting theaflavins from tea using ethanol to produce an extract having a high theaflavins content and a low content of high molecular weight thearubigins. | 2009-04-09 |
20090092691 | Formulation Based on Marigold, Aloe, and Centellae - The formulation includes between 1 and 98 parts of glycolic extract of marigold officinalis, between 1 and 98 parts of glycolic extract of aloe vera and between 1 and 98 parts of glycolic extract of centellae asiaticae. The formulation conforms an emulsion from the use of between 4 and 8% of glycolic extract of marigold officinalis, between 4 and 8% of glycolic extract of aloe vera, and between 5.5 and 9% of glycolic extract of centellae asiaticae incorporated into a base cream non ionic that includes an oily phase where it is included between 6.5 and 12% of selfemulsive wax non ionic; between 3.2 and 5.8% of estearic acid of triple pressure; between 4 and 6.4% of solid Vaseline (petroleum jelly) and between 7.6 and 9.7% of liquid Vaseline (petroleum jelly). The watery phase includes between 7 and 10.4% of glycerine; between 0.1 and 0.8% of imidozolindil urea; between a 1.6 and 3.3% of preserving universal; between 0.7 and 1.5% of polyethilenglycol 400; between 0.35 and 0.78% of Twen 80. Finally the emulsion includes the addition of demineralized water up to completing 100 g. of product. | 2009-04-09 |
20090092692 | The use of onion extracts to prevent and treat acute and chronic cardiac and vascular complications and their sequelae, as well as to resolve hematomas | 2009-04-09 |
20090092693 | Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy - Reduction of platelet counts to below 150 thousand per cubic millimeter by pharmacologic, mechanical, combined mechanical and pharmacological, or other means for the purpose of reducing the incidence and severity of vascular disease in at risk populations, for the stabilization and reversal of said disease in patients already known to suffer from such disease, as well as for the purpose of preventing and/or reducing the incidence and severity of sequelae related to such disease, whether preclinical, subclinical or overtly manifested, or whether it is presently understood to be related to said vascular disease or not. | 2009-04-09 |
20090092694 | Method of producing blood type checking reagent containing lectin - Lectin is extracted from seeds of bitter gourd (also known as balsam pear or Momordica charantia). A blood type checking reagent for checking a blood type includes the lectin. The lectin extracted from seeds of bitter gourd preferably has a molecular weight between 100,000 and 170,000 measured with polyacrylamide gel electrophoresis in existence of sodium dodecyl sulfate (SDS-PAGE). A method of checking a blood type includes the steps of: extracting lectin from seeds of bitter gourd (also known as balsam pear or Momordica charantia); preparing a blood type checking reagent containing the lectin; and checking a blood type using the blood type checking reagent. | 2009-04-09 |
20090092695 | Health supplement for lowering plasma glucose and plasma triglyceride - A kind of health supplement for lowering plasma glucose and plasma triglyceride is prepared from a mixture of dried grape skins with the flesh removed, dried grape seeds and dried grape stems, and the mixture is ground into fine powder (termed 3SG powder) according to a ratio of volume between the grape skins, the grape seeds and the grape stems found in naturally available grapes; upon treatment of the 3SG powder with ethanol, the intracellular lipid-soluble flavonoids of the 3SG powder are released to give rise to the health supplement which functions include to lower plasma glucose and plasma triglyceride, as well as to attenuate anomalous energy metabolism in diabetic, hyperglycemic, and hyperlipidemic people. | 2009-04-09 |
20090092696 | Herbal combination omega oil aphrodisiac - A method of enhancing the libido in an adult human comprising the administering of a composition, comprising an effective amount of an herbal aphrodisiac selected from the group consisting of those herbs, which are purported to enhance the libido in humans, and an effective amount of omega oils. | 2009-04-09 |
20090092697 | Extracts of polygonum multiflorum thunb., and preparation process and uses of the same - Disclosed herein are processes for preparing extract products from the root of | 2009-04-09 |
20090092698 | COMPOSITIONS AND METHODS FOR ALTERING ALPHA- AND BETA-TOCOTRIENOL CONTENT USING MULTIPLE TRANSGENES - Preparation and use of isolated nucleic acids useful in altering the oil phenotype of plants are described. Isolated nucleic acids and their encoded polypeptides are described that alter alpha- and beta-tocotrienol content in transformed seeds and oil obtained from the transformed seeds. Expression cassettes, host cells and transformed plants are described that contain the foregoing nucleic acids. | 2009-04-09 |
20090092699 | Injection Mold For Multi Insert Container - An injection mold for a multi insert container is provided, which includes a plurality of cavities, formed in order between a fixed mold and a movable mold that constitute an injection mold, for performing an insert molding of the multi insert container by stages, wherein an insert injection molding is performed simultaneously with a successive supply of molded products to the respective cavities. According to the injection mold, since a multi insert molding is performed through movement of the molded products by stages in the single mold, the workability is improved in comparison to a conventional insert molding method that uses a plurality of molds, and the molding conditions of the molded products are kept uniform to achieve a good quality of the molded products. | 2009-04-09 |
20090092700 | INJECTION MOLDING MACHINE - A second display device is provided separately from a first display device that displays information regarding molding conditions. The second display device displays character information or picture information. A control part includes a first data conversion part that data-converts the information to be displayed on the first display device and a second data conversion part that data-converts the information to be displayed on the second display device. The second display device displays information different from the first display device. | 2009-04-09 |
20090092701 | Auxiliary Carriage Combined with an Auxiliary Carriage Actuator and a Multi-Stack Molding Machine Incorporating Same - According to embodiments of the present invention, there are provided an auxiliary carriage combined with an auxiliary carriage actuator and a multi-stack molding machine incorporating same. For example, an auxiliary carriage for use in a multi-level molding machine is disclosed. The auxiliary carriage comprises a support structure configured to accept, in use, an auxiliary mold assembly; an auxiliary carriage actuator configured to be operatively coupled, in use, to the support structure, to a main carriage of the multi-level molding machine and to one of a fixed platen and a movable platen to actuate, in use, the auxiliary carriage in unison with the main carriage. | 2009-04-09 |
20090092702 | VENTED MOLD AND METHOD FOR PRODUCING MOLDED ARTICLE - The invention relates mold, particularly a mold for producing foam articles. In a preferred embodiment, the mold comprises a lid and a bowl releasingly engageable to define a mold cavity, the lid comprising: (i) a vent having a passageway for gas to escape from the mold cavity, and (ii) a plurality of grooves connected to the vent. The use of a plurality of grooves/slots in the mold cavity surface effectively acts as a siphon to draw gas away from the composition to be molded. The plurality of grooves/slots is connected to one or more vents which then allows for escape of the gas from the mold cavity to the exterior of the mold. | 2009-04-09 |
20090092703 | Phytase-Expressing Transgenic Plants - Disclosed are a transgenic plant and a transformed plant cell containing a heterologous nucleic acid that includes a sweet potato sporamin SPO promoter operably linked to a sequence encoding a polypeptide. Also disclosed are uses of the plant or cell. | 2009-04-09 |
20090092704 | Granular feed supplement - A ruminant feed composition, having a granulated core having at least one active substance and at least one layer of a coating material surrounding the core. | 2009-04-09 |
20090092705 | LIQUID-FILLED CHEWING GUM COMPOSITION - The present invention provides a chewing or bubble gum composition which includes a liquid fill composition and a gum region which includes a gum base surrounding the liquid fill, wherein the gum region includes a polyol composition including at least one polyol and having a water solubility of less than 72% by weight at 25° C. The composition may also include a coating region which surrounds the gum region. | 2009-04-09 |
20090092706 | Food Product and Process for Preparing it - Starch containing food products having controlled energy release properties are provided, wherein at least 25% by weight of the starch is contained within intact plant cells. | 2009-04-09 |
20090092707 | POLYPEPTIDES OF ALICYCLOBACILLUS SP. - Isolated polypeptides are disclosed selected from the group consisting of:
| 2009-04-09 |
20090092708 | METHOD AND SYSTEM FOR PRESERVING FOOD - The present invention includes a method for extending the shelf-life of one or more foods by exposure to one or more pulses of microwave radiation for at least seven (7) seconds. The present invention may also be used to reduce pathogenic organisms in food. The one or more foods may be packaged within a container, sealed and stored. | 2009-04-09 |
20090092709 | CLEAR FILTERED NUTRITIONAL SUPPLEMENT BEVERAGE AND FILTRATION METHOD - The present invention provides a dietary supplement, and method for making the same, comprising a glucosamine-based beverage that has the physical appearance of water, or that otherwise appears substantially transparent in its final form. The method for making the glucosamine-based beverage includes passing an aqueous glucosamine-containing solution through a multiple-step filtration process at a predetermined pH level. The first filtration step is performed with a porous volumetric fiber matrix, which is a Nominal rated filter with a cut off in the range of 0.5-1.2 microns, and preferably 0.5 microns, and at a cross-filter pressure less than or equal to 10 psi. The second filtration step is performed with a membrane filter, which is an Absolute rated filter with a cut off in the range 0.3-0.6 microns, and preferably 0.45 microns, and at a cross-filter pressure less than or equal to 10 psi. | 2009-04-09 |
20090092710 | Nutritional Supplement - The present invention relates to a nutritional supplement, comprising plant material of Mascagnia eggersiana, subspecies, ecotypes or a combination thereof. Preferably, the nutritional supplement is at least in part a shaped product. | 2009-04-09 |
20090092711 | Instant Beverage Product - An instant beverage product includes a disposable cup, a soluble ingredient disposed in a bottom portion of the disposable cup, and a sealing layer sealed at an inner surface of the disposable cup at the bottom portion thereof to seal and enclose the soluble ingredient in said disposable cup, wherein the sealing layer is removed from said disposable cup for a predetermined volume of water being added into the disposable cup to mix with the soluble ingredient to form an instant beverage. The instant beverage product is adapted to be stacked up with another instant beverage product when the bottom portion of said disposable cup is placed in the upper portion of another disposable cup through the top opening thereof to minimize a space for packing two or more the instant beverage products together. | 2009-04-09 |
20090092712 | Controlled Viscosity Oil Composition and Method of Making - The present invention relates to a sprayable oil composition comprising a blend of an oil, an edible solvent selected from the group consisting of triacetin, tripropionin, tributyrin, and ethyl acetate; and a preferably an emulsifier such as a lecithin. Advantageously, the viscosity of the blend can be controlled without interesterification of the solvent with the oil. Furthermore, such oil compositions can be effective sprayable oils such as for pan release applications while being substantially free of alcohols. | 2009-04-09 |
20090092713 | EDIBLE PRODUCTS WITH LOW CONTENT OF SATURATED AND TRANS UNSATURATED FATS - The present invention relates to a structured, fat continuous edible product, wherein the edible product contains, expressed on total product basis, less than 35 wt. % of saturated fatty acids, between 20 and 100 wt. % of a triglyceride composition, between 0 and 80 wt. % of a filler material and less than 15 wt. % of water. The triglyceride composition contains less than 50 wt. % of saturated fatty acids, less than 10 wt. % of trans unsaturated fatty acids, at least 10 wt. % of POP triglycerides, wherein P is a palmitic fatty acid, O is oleic acid, a ratio SUS/SUU of at least 1.3, a ratio SUS/SUU of at least 15, at least 90 wt. % of C8-18 fatty acids, a ratio C16/C18 saturated fatty acids of at least 1. The triglyceride composition has an SFC at 20° C. of between 3 and 55%. The present invention also relates to a process for producing such a product and to triglyceride compositions suitable for use in such a product. | 2009-04-09 |
20090092714 | COAXIAL MULTI-COMPONENT ROASTABLE FOOD ITEM - A multi-component food item and method of fabricating it to be roastable. A first food component is formed and processed to make a core that is a substantially rigid support structure having a center axis; and a different food component is coaxially coated on a coatable portion of the core to make a first of one or more food layers. Preferably a holding feature is provided to make the item roastable. An uncoated portion of the core can be used as a holding peg designed to removably engage with an externally gripping tip of an elongated roaster. A substantially axial bore hole in the core can be used to removably engage with a press-fitted internally gripping tip of a roaster. Preferably at least the outwardly exposed one of the one or more coaxial food layers is roastable in that it is improved in some palatable manner by roasting. | 2009-04-09 |
20090092715 | System for real-time characterization of ruminant feed rations - A computer-based system for characterizing in real time the nutritional components of one of more ingredients for a ruminant feed ration, including dry matter, NDF, NDFd, lignified NDF ratio, peNDF, percent starch, IVSD, and particle size for a forage material; and IVSD and particle size for a grain material. The system utilizes proprietary NIRS equations based upon prior samplings of a variety of crop species like dual-purpose corn silage, leafy corn silage, brown midrib (“BMR”) corn silage, grass (silage/dry), alfalfa (silage/dry), BMR forage sorghum, normal dent starch grain, floury endosperm starch grain, vitreous endosperm grain, and steam-flaked corn grain, and applies those equations to current samplings of a corresponding crop to predict in real time the characteristics of such forage or grain material. The real-time characterization system may also utilize the predicted data to calculate a “total ration fermentation index” value that takes into account the total NDFd and IVSD characteristics (including RAS and RBS) of the forage and starch ingredients to be used in a feed ration to ensure that the ration will not contribute too much or too little digestibility to the cow. A “flash fermentation index” identifies feed formulations, based upon the real-time characterizations of the ingredients, that are too “hot” to feed to the cows without incurring the risk of lost production and adverse health issues. | 2009-04-09 |
20090092716 | Gluten-free baked products and methods of preparation of same - The present invention provides an ingredient delivery system and methods of producing a gluten-free bakery product using an oven to produce quality gluten-free bakery products made by this method. | 2009-04-09 |